Search - tctmd.com

Displaying 41 - 60 of 66

Sort: Relevancy | Date

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

November 14, 2021

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

News Daily News

Belly Fat the Biggest Driver of Obesity-Related CVD, Says AHA

Michael O'Riordan

April 26, 2021

Despite COVID-19 Heart Disease Remains Top US Killer AHA (1).jpeg

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

December 17, 2020

Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD

News Conference News AHA 2020

Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD

November 18, 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

November 16, 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

News Conference News AHA 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

November 13, 2020

Cannabis Has No CV Benefits and Substantial Risks, Says AHA Statement

News Daily News

Cannabis Has No CV Benefits and Substantial Risks, Says AHA Statement

Yael L. Maxwell

August 06, 2020

News Daily News

COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say

March 17, 2020

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

November 22, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

November 13, 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

November 10, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.